Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681081 · ClinicalTrials.gov registry record · NA
Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02681081: Completed NA study, sponsored by University of Florida.
NCT02681081 is a NA study that has completed, run by University of Florida. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02681081, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of the study is to identify non-invasive strategies that will optimize the neurobiological environment and improve learning and memory in the treatment of chronic pain. The overall aims of the current proposal are to determine if food restriction and/or glucose administration in conjunction with a relaxation/guided imagery exercise will result in neurophysiological changes and functional improvements compared to the relaxation/guided imagery exercise alone.
Primary Outcome
Electroencephalogram (EEG) amplitude measures.
Interventions
- OTHER Control
- OTHER Intermittent Fasting
- OTHER Glucose Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-07-12 |
| Phase | NA |
What the finished NCT02681081 record still lists
NCT02681081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Control is the first listed.
NCT02681081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02681081 about?
NCT02681081 is a clinical study titled "Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness". The purpose of the study is to identify non-invasive strategies that will optimize the neurobiological environment and improve learning and memory in the treatment of chronic pain. The overall aims of the current proposal are to determine if food restriction and/or glucose administration in conjunct...
What is the current status of trial NCT02681081?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2016-02. Estimated completion is 2019-07-12.
What interventions are being tested in trial NCT02681081?
The interventions under investigation include: Control (OTHER), Intermittent Fasting (OTHER), Glucose Administration (OTHER).
Who is sponsoring clinical trial NCT02681081?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02681081's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia